Karyopharm (KPTI) EVP receives 32,415 RSUs in equity grant filing

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. executive Sohanya Cheng, EVP & Chief Commercial Officer, received an award of 32,415 shares of common stock in the form of restricted stock units on January 31, 2026. The RSUs were granted at $0 per share under the company’s 2022 Equity Incentive Plan.

The RSUs convert into common stock on a one-for-one basis, with 50% vesting on January 31, 2027 and the remaining 50% vesting on January 31, 2028. Following this grant, Cheng beneficially owns 111,921 shares of Karyopharm common stock in direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cheng Sohanya Roshan

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		A		32,415(1)	A	$0	111,921	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.

	/s/ Nancy Smith as Attorney-in-Fact for Sohanya Cheng	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Karyopharm (KPTI) EVP Sohanya Cheng report in this Form 4?

Karyopharm EVP & Chief Commercial Officer Sohanya Cheng reported receiving 32,415 restricted stock units on January 31, 2026. These stock-based awards were granted at $0 per share under the 2022 Equity Incentive Plan, increasing her directly owned Karyopharm common shares to 111,921.

How many KPTI shares were granted to Sohanya Cheng and at what price?

Sohanya Cheng was granted 32,415 shares of Karyopharm common stock in the form of RSUs at $0 per share. This reflects a stock-based compensation grant rather than an open-market purchase, and is reported as an acquisition of non-derivative securities.

How do the RSUs granted to Karyopharm (KPTI) EVP Cheng vest?

The RSUs granted to Sohanya Cheng vest in two equal installments. Fifty percent of the shares vest on January 31, 2027, and the remaining fifty percent vest on January 31, 2028. Each vested RSU converts into one share of Karyopharm common stock.

What is Sohanya Cheng’s total KPTI share ownership after this transaction?

After the January 31, 2026 RSU grant, Sohanya Cheng beneficially owns 111,921 shares of Karyopharm common stock. This total includes the 32,415 RSU-based shares reported in the filing and is held as direct ownership, according to the Form 4 disclosure.

Under which plan were the KPTI RSUs granted to EVP Sohanya Cheng?

The restricted stock units granted to Sohanya Cheng were issued under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. The filing states that the RSUs convert into Karyopharm common stock on a one-for-one basis upon vesting on the scheduled future dates.

Is the KPTI Form 4 transaction a purchase or compensation grant?

The Karyopharm Form 4 shows a compensation grant, not a market purchase. The 32,415 shares are restricted stock units awarded at $0 per share under the company’s 2022 Equity Incentive Plan, reflecting stock-based compensation to EVP & Chief Commercial Officer Sohanya Cheng.